Human Papillomavirus: Current Prevalence and Future Protection

This publication has 25 references indexed in Scilit:

• Human Papillomavirus Infection Among Sexually Active Young Women in the United States: Implications for Developing a Vaccination Strategy
  Sexually Transmitted Diseases, 2006
• Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial
  The Lancet, 2006
• The Potential of Human Papillomavirus Vaccines
  New England Journal of Medicine, 2006
• Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia
  Obstetrics & Gynecology, 2006
• Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial
  The Lancet Oncology, 2005
• The epidemiology of human papillomavirus infections
  Journal of Clinical Virology, 2005
• Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
  The Lancet, 2004
• Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine
  JNCI: Journal of the National Cancer Institute, 2004
• Detection of human papillomavirus DNA in self-administered vaginal swabs as compared to cervical swabs
  International Journal of STD & AIDS, 2003
• A Controlled Trial of a Human Papillomavirus Type 16 Vaccine
  New England Journal of Medicine, 2002